ACC: American College of Cardiology

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual Scientific Session.

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in reducing cardiovascular death did not significantly differ across baseline bilirubin tertiles.

Panelists explored responsible, patient-centered use of artificial intelligence (AI) in cardiovascular care at the American College of Cardiology 2025 Annual Scientific Session.

Anna Mueller, MD, Mount Sinai, presented the findings at the American College of Cardiology 2025 Annual Scientific Session and explained that broader adoption of imaging assessments will depend on further research.

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to determine the effect on outcomes, Marc Humbert, MD, PhD, University Paris-Saclay, explains in an interview.

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk patients with heart failure.

MACRO trial researchers said adapting to the COVID-19 pandemic mid-trial may have undercut the efficacy of the intervention, but it still showed promise.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Despite showing no overall benefit, an in-home paramedic visit appeared to help women avoid readmissions more than men.

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type 2 diabetes.

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, elevated heart failure risk after ovary removal, and more.

New research suggests areas with higher concentrations of microplastics also have higher rates of chronic disease.

Our top coverage from the 72nd American College of Cardiology (ACC) Scientific Session included results from the STELLAR, CLEAR Outcomes, ACCESS, and HALO trials.

Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.

The findings of the ACCESS study show the complex challenge of improving medication adherence among the most fragile members of society.

Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed that the therapy caused a sustained, dose-dependent reduction in plasma aldosterone by more than 70% without reducing cortisol.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.

Braden Manns, MD, MSc, a nephrologist and health economics researcher at the University of Calgary in Canada, will present the results of a randomized trial evaluating the impact of removing co-payments for drugs that treat chronic conditions on cardiovascular outcomes during the American College of Cardiology Scientific Sessions in New Orleans, Louisiana, on Sunday, March 5.

Patients who cardiologists see once every few months are getting handed over to pharmacists who can monitor them more frequently and get them to their goals, said Crystal Zhou, PharmD, assistant professor of Clinical Pharmacy at the University of California, San Francisco (UCSF).

Patients often have comorbidities that make it important to consider them holistically and not bucket them into one disease state, and the findings on rivaroxaban show broad benefits and a favorable risk-benefit profile, said Marc Bonaca, MD, MPH, of CPC Clinical Research and CPC Community Health and the University of Colorado School of Medicine.

Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.